Weak Q4 results drag Jubilant Pharmova shares nearly 4% from day’s high

Jubilant Pharmova shares came under pressure on Friday after the company reported a mixed set of Q4FY26 earnings, with profitability and margins declining despite strong revenue growth. The stock fell nearly 3.9% from its intraday high of ₹1,025 to a low of ₹988 during the session. At around 2:41 PM, the stock was trading at ₹1,005, down 0.66% for the day.

The pharmaceutical company reported a 23% year-on-year decline in net profit to ₹119 crore for the quarter ended March 2026, compared to ₹154 crore in the corresponding quarter last year.

Revenue from operations, however, rose 18.8% YoY to ₹2,290 crore against ₹1,928 crore in Q4FY25, indicating healthy business momentum across segments.

EBITDA for the quarter came in at ₹339.3 crore, marginally lower by 1.6% compared to ₹345 crore a year ago. EBITDA margin contracted sharply to 14.8% from 17.9% in the year-ago period, reflecting pressure on operating profitability despite higher sales growth.

The market reaction appeared to be driven primarily by the margin compression and decline in earnings, even as topline growth remained strong. Investors also tracked the sharp difference between revenue expansion and operating profit trends, which pointed toward higher costs impacting profitability during the quarter.

On the stock-specific front, Jubilant Pharmova touched an intraday high of ₹1,025 before witnessing selling pressure. The stock moved within a broad range of ₹988–₹1,025 during the session, while trading volumes crossed 4.24 lakh shares.

Jubilant Pharmova operates across pharmaceuticals, radiopharma, contract research and development services, allergy therapy and drug discovery solutions, with business presence across domestic and global markets.

Disclaimer: This article is based on company earnings updates and market data. It is intended for informational purposes only and should not be construed as investment advice.